SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Nanomedical Drug Delivery for Neurodegenerative Diseases
- 1st Edition - March 10, 2022
- Editors: Awesh K. Yadav, Rahul Shukla, S.J.S. Flora
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 5 4 4 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 0 1 - 0
Nanomedical Drug Delivery for Neurodegenerative Diseases opens the door for promising approaches and advances in the diagnosis and treatment of various neurodegenerative diseas… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNanomedical Drug Delivery for Neurodegenerative Diseases opens the door for promising approaches and advances in the diagnosis and treatment of various neurodegenerative diseases. The contents of the book comprise all the aspects related to the design, synthesis, and application of different nanodrug delivery systems in the treatment of neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and motor neuron diseases. This book explores how nanoparticulate drug carriers can improve therapeutic efficacy by selecting a suitable design strategy. Nanomedical Drug Delivery for Neurodegenerative Diseases is a valuable resource for graduates, clinical researchers, and other scientists working to minimize the challenges to deliver the drugs and genes in a more efficient and targeted manner for the treatment of neurodegenerative diseases.
- Includes design, synthesis and applications of drug delivery systems
- Explores the role of nanotechnology in the diagnosis and treatment of neurodegenerative disorders
- Reviews applications for the management of Parkinson's disease, Alzheimer's disease, Huntington's disease, and motor neuron diseases
- Discusses extracellular vesicles and mitochondria-targeted bioactive delivery systems
- Details how nanocarrier-based delivery is useful to improve efficacy and cure
Basic and clinical researchers in neuroscience, neuropharmacology, and pharmacology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1: Aetiology and pathophysiology of neurodegenerative disorders
- Abstract
- 1: Introduction
- 2: Amyloidoses
- 3: Tauopathies
- 4: Synucleinopathies
- 5: TDP-43 proteinopathies
- 6: Conclusion
- Chapter 2: Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer’s disease
- Abstract
- 1: Introduction
- 2: Emerging research in targeted nanoparticles for treating Alzheimer’s disease
- 3: Polymeric nanoparticles
- 4: Lipidic nanoparticles
- 5: Lipid nanoparticles (LNPs)
- 6: Liquid crystals (LCs)
- 7: Inorganic nanoparticles
- 8: Conclusion
- Chapter 3: Neurodegenerative disorders due to inhalation of various small particles
- Abstract
- 1: Introduction
- 2: Different exposures to inhalation and their sources
- 3: Bio-kinetics of inhaled particles
- 4: Detrimental effects induced by small inhaled particles on CNS
- 5: Possible mechanisms for inhaled particles associated with CNS disorders
- 6: Genetics and epigenetics expression in response to PM
- Chapter 4: Lipid nanocarrier-based drug delivery for the treatment of brain-related disorders
- Abstract
- Acknowledgment
- 1: Introduction
- 2: Drug delivery approaches for neurodegenerative diseases
- 3: Lipid carrier for drug delivery in neurodegenerative disease
- 4: Conclusion
- Chapter 5: Nanomedical drug delivery for neurodegenerative disease
- Abstract
- 1: Introduction
- 2: Drug delivery systems based on nanotechnology for Alzheimer’s disease management
- 3: Future of drug delivery systems based on nanomedicine
- 4: Conclusion
- Chapter 6: siRNA polymer conjugates for the delivery of RNAi therapeutics for the treatment of Parkinson’s disease
- Abstract
- 1: Introduction
- 2: About siRNA
- 3: Advantages of siRNA-mediated therapeutics
- 4: RNA interference (RNAi) therapeutics
- 5: Challenges in brain delivery of siRNA
- 6: siRNA therapeutics in Parkinson’s disease
- 7: siRNA polymer conjugates
- 8: Other delivery strategies using siRNA in Parkinson’s disease
- 9: Discussion
- 10: Conclusion
- Chapter 7: Potential of nanoparticles as novel therapeutics against Alzheimer’s disease
- Abstract
- 1: Introduction
- 2: Nanoparticle-based drug delivery to the brain
- 3: Nanoparticulate carriers for brain delivery
- 4: Nanotechnology for Alzheimer management
- 5: Toxicity aspects
- 6: Clinical aspects
- 7: Regulatory aspects
- 8: Conclusion
- Conflict of interest
- Chapter 8: Recent trends of extracellular vesicles for therapeutic intervention of brain-related diseases
- Abstract
- 1: Introduction
- 2: Types of extracellular vesicles
- 3: Role of extracellular vesicles in neurological diseases
- 4: Extracellular vesicles in CNS and their application in diagnosis
- 5: Extracellular vesicles as therapeutics in CNS disorders
- 6: Future prospective
- 7: Conclusions
- Conflicts of interest
- Chapter 9: Mitochondria-targeted drug delivery systems for the effective treatment of neurodegenerative disorders
- Abstract
- 1: Mitochondria: A promising target in neurodegenerative diseases
- 2: Mitochondria-targeted pharmacological agents used in the management of neurodegenerative diseases
- 3: Mitochondria-targeted drug delivery system in neurodegeneration
- 4: Conclusions
- Chapter 10: Recent trends of theranostic applications of nanoparticles in neurodegenerative disorders
- Abstract
- 1: Introduction
- 2: Cerebral barriers
- 3: Brain receptors
- 4: BBB transporter systems
- 5: Mechanisms of drug transport across the BBB
- 6: Neurodegenerative disorders
- 7: Theranostic application of nanoparticles (NPs)
- 8: Conclusion
- Chapter 11: Role of nanoparticles in neurotoxicity
- Abstract
- 1: Introduction
- 2: Classification of nanoparticles
- 3: The entry of nanoparticles into the brain
- 4: The fate and kinetics of nanoparticles in brain
- 5: Neurotoxicity: Classification and mechanism
- 6: Neurotoxicity of nanoparticles
- 7: Conclusion and future aspects
- Funding support
- Chapter 12: Metal nanoparticles for neurodegenerative diseases
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Emergence of metal nanoparticles
- 3: Role of nanoparticles in the diagnosis and treatment of neurodegenerative diseases
- 4: Nonmetallic nanoparticles for neurodegenerative diseases
- 5: Future perspectives and challenges
- 6: Conclusion
- Chapter 13: Nano-based phytodrug delivery systems for the management of neurodegenerative disorders
- Abstract
- 1: Introduction
- 2: Neurodegenerative disorders (NDs)
- 3: Conclusions
- Chapter 14: Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer’s disease
- Abstract
- 1: Introduction
- 2: Alzheimer’s disease pathophysiology
- 3: Characteristics of Alzheimer’s disease diagnosis and therapeutic approaches
- 4: FDA-authorized Alzheimer’s disease drug treatment
- 5: AD emerging nanotechnology research
- 6: Drug delivery method of nanoparticles and its significance
- 7: AD therapeutic nano drug delivery methods
- 8: Potential AD nanotherapeutic strategies
- 9: Nanoparticle-based drug delivery systems for delivery of AChE inhibitor
- 10: Future challenges and approaches
- 11: Conclusion
- Chapter 15: Nanomaterial-based drug delivery systems as tools for targeted therapy of neurodegenerative diseases
- Abstract
- 1: Introduction
- 2: Neurodegenerative diseases
- 3: Obstacles of drug delivery to brain targeting
- 4: Strategies to improve delivery
- 5: Nanomaterial-based drug delivery systems for neurodegenerative diseases
- 6: Conclusion and future prospective
- Chapter 16: Sample preparation techniques for quantitative analysis in brain pharmacokinetics: Application to neurodegenerative diseases
- Abstract
- 1: Introduction
- 2: Sample preparation techniques for brain sample analysis
- 3: Pharmacokinetic and brain sample processing
- 4: Quantitative analysis using HPLC, LC-MS/MS, and GC–MS
- 5: Conclusion
- Index
- No. of pages: 282
- Language: English
- Edition: 1
- Published: March 10, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780323855440
- eBook ISBN: 9780323898010
AY
Awesh K. Yadav
Dr. Awesh K. Yadav has received his B.Pharm, M.Pharm, and PhD from Dr. Hari Singh Gour University Sagar (MP). He is currently working as Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research Raebareli, India. He has more than 15 years of teaching and industrial experience in various institutes and industries. He has written dozens of quality research publications in journals of national and international repute. He has also published four books and seven book chapters. He has been awarded the best citation award for his publication in the International Journal of Pharmaceutics in 2005. Dr. Yadav’s current research interest includes targeted and controlled novel drug delivery systems for the delivery of various bioactives such as anticancer drugs, anti-Alzheimer's drugs, anti-Parkinson drugs, anti-malarial drugs, sun-screening agents, etc.
Affiliations and expertise
Assistant Professor, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research Raebareli, A Transit Campus at Bijnor-Sesendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, Uttar Pradesh, IndiaRS
Rahul Shukla
Dr. Rahul Shukla is currently working as an Assistant Professor (Contract) at Department of Pharmaceutics, NIPER Raebareli, India, He has a PhD in Pharmaceutical Sciences from CSIR CDRI and J.N.U New Delhi, India, an M.Pharm from IIT BHU,Varanasi, India and B.Pharm from Jamia Hamdard, New Delhi. He has more than ten years of research and academic experience with more than 30 publications and 10 book chapters to his credit. He has filed 7 Indian Patent and 1 Copyright. Recently he has edited a book on the Role of Novel Drug Delivery Vehicles in Nanobiomedicine. His current research interests include targeted drug delivery systems, particle engineering, controlled delivery for neurodegenerative diseases, dendrimer mediated drug delivery, solubilization and bioavailability enhancements.
Affiliations and expertise
Assistant Professor, Department of Pharmeceutics, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, IndiaSF
S.J.S. Flora
Dr. S. J. S. Flora is the Former Director of the National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Uttar Pradesh, India, since 2016. Dr. Flora was head of Division of Pharmacology and Toxicology at Defense Research and Development Establishment, Gwalior, India. He earned his PhD in 1985 from CSIR-Indian Toxicology Research Center, Lucknow, and was a postdoctoral research associate at Utah State University, USA. His most highlighted contribution has been the development of a new drug for the therapy of chronic arsenic poisoning, which was approved by the Drug Controller General of India (DCGI). He has published more than 350 research papers, 75 review articles/chapters, 18 patents, and more than 16,000 citations. He has published 6 books including the prestigious Handbook of Arsenic Toxicology and the Handbook of Arsenic Toxicology and the Handbook on Biological Warfare Preparedness published by Elsevier/Academic Press (USA).
Affiliations and expertise
Former Director, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, IndiaRead Nanomedical Drug Delivery for Neurodegenerative Diseases on ScienceDirect